NFKB1 and breast carcinoma: To determine the optimal dose of bortezomib to assess NF-κB activity, we first examined sensitivity of MCF7 and T47D to bortezomib treatment and observed that breast cancer lines, especially MCF7, were relatively resistant to bortezomib.